Moleculin Biotech (MBRX) said Tuesday it received regulatory approval in Ukraine to start recruiting for a phase 3 trial of annamycin plus cytarabine to treat relapsed or refractory acute myeloid leukemia, a type of cancer.
The first 75 to 90 subjects in the trial's part A will receive high-dose cytarabine, or HiDAC, combined with either placebo or various doses of annamycin, the company said.
For part B, roughly 244 additional subjects will receive either HiDAC plus placebo or HiDAC plus the optimum dose of annamycin, up from 240 subjects. Moleculin said the increase in the number of subjects represents the "statistical 'cost' of the additional interim unblinding."
Moleculin Biotech said it remains on track to treat a first subject in the phase 3 trial in Q1.
Shares were down over 16% in recent trading.
Price: 0.59, Change: -0.12, Percent Change: -16.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。